Last edition
News about "multiple sclerosis"
Alembic Pharmaceuticals Secures US FDA Nod for Fingolimod Capsules
Alembic Pharmaceuticals receives US FDA approval for fingolimod capsules, expanding access to a key multiple sclerosis treatment in the US market.
Multiple Sclerosis | 27/04/2026 | By News Bureau
Roche Reports Strong Phase III Results for Fenebrutinib in Multiple Sclerosis
Roche’s investigational drug fenebrutinib shows significant reduction in relapse rates and disease activity in multiple sclerosis, offering potential for improved long-term outcomes in patients.
Multiple Sclerosis | 23/04/2026 | By News Bureau | 110
Roche Secures CE Mark for Blood-Based Test to Monitor Multiple Sclerosis
Roche’s Elecsys NfL test receives CE approval, offering a simple blood-based method to detect neuroinflammation in multiple sclerosis, improving monitoring access and supporting more timely, personalised disease management.
Multiple Sclerosis | 14/04/2026 | By News Bureau
Roche Pharma India partners with the Government of Punjab to launch NeuroSakhi, a patient support and awareness programme aimed at improving diagnosis, care pathways and treatment access for women with multiple sclerosis.
Multiple Sclerosis | 13/03/2026 | By News Bureau | 122
Nektar Therapeutics and UCSF collaborate to study TNFR2 agonist NKTR-0165 in multiple sclerosis, aiming to explore its potential for neuroprotection and reduced neurodegeneration.
Multiple Sclerosis | 18/02/2026 | By News Bureau | 159
In the pivotal FENtrepid trial, Roche’s BTK inhibitor fenebrutinib demonstrated a meaningful reduction in disability progression in Primary Progressive Multiple Sclerosis (PPMS), performing at least on par with OCREVUS—the current standard and only approved treatment for PPMS.
Multiple Sclerosis | 15/11/2025 | By Dineshwori | 282
Cycle Pharma Acquires Banner Life Sciences
BAFIERTAM will become Cycle’s second branded product for the treatment of MS alongside TASCENSO ODT® (fingolimod).
Multiple Sclerosis | 14/01/2025 | By Aishwarya | 919
First Use of Kyverna KYV-101 in Patients with Progressive Multiple Sclerosis Published
Kyverna Therapeutics, Inc. has announced about a recent report published in Med that describes the first use of KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, in two patients suffering from progressive multiple sclerosis (MS).
Multiple Sclerosis | 30/03/2024 | By Manvi | 1080
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy